MR Spectroscopy (MRS) provides early biomarkers of brain injury and treatment response in neonates with hypoxic-ischemic encephalopathy. We present preliminary data from the High-dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) Trial (NCT02811263), comparing quality assurance parameters across MR vendors. Overall, we have been able to analyze MRS data obtained from 85% of patients who underwent MRI, although this rate is lower at sites operating GE MR systems. 92% of spectra met quality standards, with slight differences in FWHM and SNR by vendor. Overall, these data demonstrate the feasibility of obtaining reliable MRS data in a multicenter neonatal randomized controlled trial.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords